The sellers would have picked up options at 3.75c some time ago.
There still needs to be private payers and bigger exposure away from Lymphedema to really move forward. As much as the product to measure Lymphoedema is excellent. The majority do not see this as a major market.
This is why I see Renal and Heart news as the real moving force and will need to continue in the future
Cheers
- Forums
- ASX - By Stock
- IPD
- Ann: FDA Grants Breakthrough Device Designation for Renal Failure
Ann: FDA Grants Breakthrough Device Designation for Renal Failure, page-12
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IPD (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.4¢ |
Change
-0.003(4.48%) |
Mkt cap ! $129.4M |
Open | High | Low | Value | Volume |
6.5¢ | 6.8¢ | 6.3¢ | $106.5K | 1.635M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 103932 | 6.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.9¢ | 200000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 103932 | 0.064 |
2 | 57113 | 0.063 |
2 | 40629 | 0.062 |
2 | 25000 | 0.061 |
4 | 562000 | 0.060 |
Price($) | Vol. | No. |
---|---|---|
0.069 | 200000 | 1 |
0.070 | 170769 | 3 |
0.071 | 156845 | 2 |
0.072 | 200000 | 1 |
0.073 | 1000000 | 1 |
Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
Featured News
IPD (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online